451 related articles for article (PubMed ID: 33878488)
1. Disease modifying therapies in relapsing-remitting multiple sclerosis: A systematic review and network meta-analysis.
Liu Z; Liao Q; Wen H; Zhang Y
Autoimmun Rev; 2021 Jun; 20(6):102826. PubMed ID: 33878488
[TBL] [Abstract][Full Text] [Related]
2. Comparative safety of high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
Śladowska K; Kawalec P; Holko P; Osiecka O
Neurol Sci; 2022 Sep; 43(9):5479-5500. PubMed ID: 35713731
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.
Gonzalez-Lorenzo M; Ridley B; Minozzi S; Del Giovane C; Peryer G; Piggott T; Foschi M; Filippini G; Tramacere I; Baldin E; Nonino F
Cochrane Database Syst Rev; 2024 Jan; 1(1):CD011381. PubMed ID: 38174776
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
Li H; Hu F; Zhang Y; Li K
J Neurol; 2020 Dec; 267(12):3489-3498. PubMed ID: 31129710
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis.
Fogarty E; Schmitz S; Tubridy N; Walsh C; Barry M
Mult Scler Relat Disord; 2016 Sep; 9():23-30. PubMed ID: 27645339
[TBL] [Abstract][Full Text] [Related]
6. Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: A Network Meta-Analysis.
Lucchetta RC; Tonin FS; Borba HHL; Leonart LP; Ferreira VL; Bonetti AF; Riveros BS; Becker J; Pontarolo R; Fernandez-Llimós F; Wiens A
CNS Drugs; 2018 Sep; 32(9):813-826. PubMed ID: 30014314
[TBL] [Abstract][Full Text] [Related]
7. Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis.
McCool R; Wilson K; Arber M; Fleetwood K; Toupin S; Thom H; Bennett I; Edwards S
Mult Scler Relat Disord; 2019 Apr; 29():55-61. PubMed ID: 30677733
[TBL] [Abstract][Full Text] [Related]
8. Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis.
Siddiqui MK; Khurana IS; Budhia S; Hettle R; Harty G; Wong SL
Curr Med Res Opin; 2018 Aug; 34(8):1361-1371. PubMed ID: 29149804
[TBL] [Abstract][Full Text] [Related]
9. High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing-Remitting Multiple Sclerosis.
Freeman L; Longbrake EE; Coyle PK; Hendin B; Vollmer T
CNS Drugs; 2022 Dec; 36(12):1285-1299. PubMed ID: 36350491
[TBL] [Abstract][Full Text] [Related]
10. Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis.
Samjoo IA; Worthington E; Drudge C; Zhao M; Cameron C; Häring DA; Stoneman D; Klotz L; Adlard N
J Comp Eff Res; 2020 Dec; 9(18):1255-1274. PubMed ID: 33090003
[No Abstract] [Full Text] [Related]
11. Impact of disease-modifying therapies on MRI and neurocognitive outcomes in relapsing-remitting multiple sclerosis: a protocol for a systematic review and network meta-analysis.
Lees S; Dicker M; Ku JE; Chaganti V; Mew-Sum M; Wang N; Smith A; Oldmeadow C; Goon WL; Bevan M; Lang D; Hinwood M
BMJ Open; 2021 Nov; 11(11):e051509. PubMed ID: 34728450
[TBL] [Abstract][Full Text] [Related]
12. Impact of disease-modifying therapies on MRI outcomes in patients with relapsing -remitting multiple sclerosis: A systematic review and network meta-analysis.
Bose D; Ravi R; Maurya M; Pushparajan L; Konwar M
Mult Scler Relat Disord; 2022 May; 61():103760. PubMed ID: 35381534
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy and safety of disease-modifying therapies in patients with relapsing multiple sclerosis: A systematic review and network meta-analysis.
Chen C; Zhang E; Zhu C; Wei R; Ma L; Dong X; Li R; Sun F; Zhou Y; Cui Y; Liu Z
J Am Pharm Assoc (2003); 2023; 63(1):8-22.e23. PubMed ID: 36055929
[TBL] [Abstract][Full Text] [Related]
14. Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis.
Huisman E; Papadimitropoulou K; Jarrett J; Bending M; Firth Z; Allen F; Adlard N
BMJ Open; 2017 Mar; 7(3):e013430. PubMed ID: 28283486
[TBL] [Abstract][Full Text] [Related]
15. Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis.
Zimmermann M; Brouwer E; Tice JA; Seidner M; Loos AM; Liu S; Chapman RH; Kumar V; Carlson JJ
CNS Drugs; 2018 Dec; 32(12):1145-1157. PubMed ID: 30141001
[TBL] [Abstract][Full Text] [Related]
16. Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia.
Alharbi MA; Aldosari F; Althobaiti AH; Abdullah FM; Aljarallah S; Alkhawajah NM; Alanazi M; AlRuthia Y
BMC Health Serv Res; 2023 May; 23(1):552. PubMed ID: 37237257
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of monoclonal antibody therapies for relapsing remitting multiple sclerosis: A network meta-analysis.
Xu X; Chi S; Wang Q; Li C; Xu B; Zhang J; Chen X
Mult Scler Relat Disord; 2018 Oct; 25():322-328. PubMed ID: 30195200
[TBL] [Abstract][Full Text] [Related]
18. Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing-remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches.
Berardi A; Siddiqui MK; Treharne C; Harty G; Wong SL
Curr Med Res Opin; 2019 Aug; 35(8):1371-1378. PubMed ID: 30786783
[No Abstract] [Full Text] [Related]
19. Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis.
Samjoo IA; Drudge C; Walsh S; Tiwari S; Brennan R; Boer I; Häring DA; Klotz L; Adlard N; Banhazi J
J Comp Eff Res; 2023 Jul; 12(7):e230016. PubMed ID: 37265062
[No Abstract] [Full Text] [Related]
20. Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial.
Brittain G; Petrie J; Duffy KEM; Glover R; Hullock K; Papaioannou D; Roldan E; Beecher C; Bursnall M; Ciccarelli O; Coles AJ; Cooper C; Giovannoni G; Gabriel I; Kazmi M; Kyriakou C; Nicholas R; Paling D; Peniket A; Scolding N; Silber E; de Silva T; Venneri A; Walters SJ; Young C; Muraro PA; Sharrack B; Snowden JA;
BMJ Open; 2024 Feb; 14(2):e083582. PubMed ID: 38316583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
